Explore 3 Stock Ideas & Industry Insights Download Free Report

News

LCI Industries Refiles HSR Antitrust Notice for Patrick Merger

LCI Industries filed an 8-K current report on September 10, 2026, disclosing that it voluntarily withdrew and then refiled its Hart-Scott-Rodino antitrust notification related to its pending merger with Patrick Industries, resetting the applicable HSR waiting period.

Vinay Lochav | 10 September 2026

Nike Director Maria Henry Receives Restricted Share Grant

A statement of changes in beneficial ownership was filed on September 10, 2026, disclosing that Nike, Inc. director Maria Henry received a restricted stock grant on September 8, 2026, under the company's Stock Incentive Plan.

Aditi Sarkar | 10 September 2026

Sionna Therapeutics (NASDAQ: SION): Regrouping After a Cystic Fibrosis Setback

Sionna is a clinical-stage biopharmaceutical company developing medicines for cystic fibrosis (CF), a genetic disease driven by defects in the CFTR protein. The company went public onNasdaqin February 2025 and has pursued a differentiated approach aimed at stabilizing the NBD1 region of CFTR, alongside …

Nitish Kishor | 10 September 2026

CEL-SCI Corporation (NYSE American: CVM): Multikine's Phase 3 Progress in Focus

CEL-SCI is a clinical-stage immunotherapy company whose lead asset, Multikine (leukocyte interleukin injection), is being developed for certain head and neck cancers. In 2026 the company advanced on several fronts. On July 13, 2026, it launched a global, roughly 212-patient confirmatory registration Phase 3 …

Nitish Kishor | 10 September 2026

Artelo Biosciences (NASDAQ: ARTL): Progress Across a Three-Program Pipeline

Artelo Biosciences (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company built around the biology of lipids and the endocannabinoid system. Its portfolio spans oncology-supportive care, pain and metabolic health. In its second-quarter 2026 update, released in August, the company reiterated progress across three programs and …

Nitish Kishor | 10 September 2026

iTonic Holdings (NASDAQ: ITOC): Listing Compliance and Legal Overhang Explained

iTonic Holdings Ltd (NASDAQ: ITOC) is a healthcare technology company focused on brachytherapy, a form of cancer treatment that places radioactive sources inside or next to a tumor. The company develops treatment-planning systems and related software used in radiotherapy, and it is headquartered in …

Nitish Kishor | 10 September 2026

Pulmatrix (NASDAQ: PULM): The Pending Reverse Merger With Eos SENOLYTIX

Pulmatrix, Inc (NASDAQ: PULM) is a clinical-stage biotechnology company historically known for its iSPERSE inhaled dry-powder platform. In recent quarters it has functioned largely as a small, cash-conserving Nasdaq-listed shell seeking a strategic combination.

Nitish Kishor | 10 September 2026

CalciMedica (NASDAQ: CALC): FDA Alignment on Acute Pancreatitis Endpoints

CalciMedica, Inc (NASDAQ: CALC) is a clinical-stage biopharmaceutical company developing Auxora, an intravenous inhibitor of calcium release-activated calcium (CRAC) channels. Its primary focus is acute pancreatitis (AP), a serious inflammatory condition with no approved targeted therapy.

Nitish Kishor | 10 September 2026

Bio Green Med Solution (NASDAQ: BGMS): Understanding the Fire-Safety Company's Pending Merger

Bio Green Med Solution, Inc (NASDAQ: BGMS) is headquartered in Kuala Lumpur, Malaysia, and operates in the industrials sector. Its business centers on distributing, trading and installing protective and fire-safety materials and equipment, along with fire protection and prevention systems. Despite the "Med" in …

Nitish Kishor | 10 September 2026

Rafarma Pharmaceuticals (OTC: RAFA): A Sub-Penny Generic Drugmaker's Limited Disclosure

Rafarma Pharmaceuticals describes itself as a multi-product pharmaceutical company focused onManufacturingand selling generic antibiotics, specialty medicines and anti-cancer drugs, with operations oriented toward Russian and international markets. The company is incorporated in Wyoming and its shares trade on the OTC Markets rather than a …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…